APGE Apogee Therapeutics, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
15:09
May 29
May 29
The author highlights Chris Staral's past holdings and return under Triple Helix, but this is a historical research summary and watchlist, not an active position or forward call.
LOW
11:59
May 27
May 27
P2b data readout shows high dose underperforming mid dose in every metric, directly invalidating the core "higher exposure = greater efficacy" bull thesis that drove the stock; management narrative has collapsed per speaker's clinical analysis.
MED
11:50
May 27
May 27
Phase 2b high-dose trial data for APGE showed high dose underperforming mid dose across all metrics, directly contradicting management's long-standing "underdosing" narrative; speaker draws unfavorable comparison to Lebri's P2b results.
MED
11:27
May 27
May 27
APGE 16-week Part B data released; high-dose result described as underwhelming, pink eye indication viewed positively — mixed read, no explicit directional position stated.
MED
11:27
May 27
May 27
Author expresses bullish conviction on NKTR with a long position while noting APGE's upcoming data catalyst, suggesting a positive outlook for NKTR.
LOW
10:40
May 27
May 27
Clinical trial result showing higher dosing failed to improve efficacy for APGE, with dose-response relationship inverted — fundamental negative data event.
LOW
20:04
May 26
May 26
Part B 16-week clinical data readout scheduled for tomorrow morning — specific binary catalyst with timing, no directional view from speaker.
LOW
13:38
May 19
May 19
Buy SYRE, ORKA, and APGE as the triple combination appears undervalued relative to alternatives, with potential upside from oncology inclusion.
HIGH
12:41
May 19
May 19
Avoid SYRE, ORKA, and APGE due to overvaluation vs. a private competitor with superior bispecific platform, broader pipeline, and lower trial risk; the author questions the durability of their clinical data and rationale for separate companies.
HIGH
16:10
May 07
May 07
The tweet lists four biotech tickers with no directional commentary or forward-looking thesis, merely sharing a link without expressing a bullish or bearish view.
HIGH
00:01
Apr 29
Apr 29
Long APGE: its YTE technology enables effective sparse dosing, giving it a competitive advantage over alternatives without YTE.
HIGH
13:42
Apr 28
Apr 28
Short/avoid ORKA, APGE, and NTLA; bullish survey data is flawed because it ignores generic competition that will erode the advantage of sparser dosing.
HIGH
20:33
Apr 20
Apr 20
Bearish view on APGE due to the implied failure of its key OX40 combination drug candidate, which removes a major value catalyst and suggests underlying pipeline weakness is not fully priced in.
HIGH
12:59
Apr 18
Apr 18
Bearish view on APGE as management's narrative regarding Lebrikizumab underdosing is contradicted by maintenance data showing better efficacy at lower exposure levels, indicating thesis creep and fabricated claims.
HIGH
About APGE Analyst Coverage
Buzzberg tracks APGE (Apogee Therapeutics, Inc. Common Stock) across 2 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 15 total trade ideas tracked.